M

Middle East Pharmaceutical Industries Company SJSC
SAU:4016

Watchlist Manager
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Watchlist
Price: 121.2 SAR 1.68% Market Closed
Market Cap: 2.4B SAR
Section:
Profitability Summary
Profitability Summary
Past Growth
Margins
Return on Capital
Free Cash Flow
See Also

Profitability Summary

Middle East Pharmaceutical Industries Company SJSC's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less
0
Revenue
+0%
Sep 30, 2024 596.5m
Jun 30, 2024 515.4m
Mar 31, 2024 507.6m
Dec 31, 2023 338.4m
0
Operating Income
+0%
Sep 30, 2024 122m
Jun 30, 2024 115.1m
Mar 31, 2024 111.4m
Dec 31, 2023 78.2m
0
Net Income
+0%
Sep 30, 2024 100.9m
Jun 30, 2024 97m
Mar 31, 2024 93.2m
Dec 31, 2023 65.8m

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Middle East Pharmaceutical Industries Company SJSC

Revenue
596.5m SAR
Cost of Revenue
-231.5m SAR
Gross Profit
364.9m SAR
Operating Expenses
-242.9m SAR
Operating Income
122m SAR
Other Expenses
-21.2m SAR
Net Income
100.9m SAR

Margins Comparison
Middle East Pharmaceutical Industries Company SJSC Competitors

Country Company Market Cap Gross
Margin 		Operating
Margin 		Net
Margin
SA
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
2.4B SAR
61%
20%
17%
US
Eli Lilly and Co
NYSE:LLY
819.5B USD
81%
38%
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
393B USD
69%
26%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK
85%
48%
35%
CH
Roche Holding AG
SIX:ROG
242.5B CHF
73%
32%
20%
US
Merck & Co Inc
NYSE:MRK
233.7B USD
81%
36%
27%
UK
AstraZeneca PLC
LSE:AZN
177.6B GBP
82%
23%
13%
CH
Novartis AG
SIX:NOVN
199.6B CHF
75%
32%
23%
IE
Endo International PLC
LSE:0Y5F
166.1B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
148.1B USD
74%
25%
13%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Middle East Pharmaceutical Industries Company SJSC Competitors

Country Company Market Cap ROE ROA ROCE ROIC
SA
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
2.4B SAR
33%
22%
37%
27%
US
Eli Lilly and Co
NYSE:LLY
819.5B USD
85%
15%
39%
22%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
393B USD
20%
8%
19%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK
81%
26%
71%
33%
CH
Roche Holding AG
SIX:ROG
242.5B CHF
40%
13%
29%
22%
US
Merck & Co Inc
NYSE:MRK
233.7B USD
42%
15%
28%
21%
UK
AstraZeneca PLC
LSE:AZN
177.6B GBP
18%
7%
17%
14%
CH
Novartis AG
SIX:NOVN
199.6B CHF
27%
12%
23%
17%
IE
Endo International PLC
LSE:0Y5F
166.1B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
148.1B USD
9%
4%
9%
8%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 241,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.